
NØIE offers a clinically-proven, science-backed, and dermatologically tested approach to individual skincare, focusing on concerns like acne, rosacea, eczema, and texture issues. Their business model is subscription-based, providing customized routines powered by artificial intelligence. They differentiate by offering personalized formulations, unlimited reformulations, and a 'Skin Improvement Guarantee,' ensuring customer satisfaction. The company emphasizes the psychological impact of skin conditions and aims to improve users' quality of life. With over 80,000 users contributing feedback, NØIE continually refines its algorithms for more accurate solutions, positioning itself as a leader in personalized, science-driven skincare.

NØIE offers a clinically-proven, science-backed, and dermatologically tested approach to individual skincare, focusing on concerns like acne, rosacea, eczema, and texture issues. Their business model is subscription-based, providing customized routines powered by artificial intelligence. They differentiate by offering personalized formulations, unlimited reformulations, and a 'Skin Improvement Guarantee,' ensuring customer satisfaction. The company emphasizes the psychological impact of skin conditions and aims to improve users' quality of life. With over 80,000 users contributing feedback, NØIE continually refines its algorithms for more accurate solutions, positioning itself as a leader in personalized, science-driven skincare.
Founded: 2019 (Copenhagen, Denmark)
What they do: AI-driven, individualized subscription skincare with personalized formulations and unlimited reformulations
Funding: $12M Series A (announced May 6, 2021) led by Talis Capital
Founders: Daniel Jensen and Chris Christiansen
Users / data: Over 80,000 users contributed feedback used to refine algorithms
Personalized treatment for common skin conditions and texture concerns (acne, rosacea, eczema, psoriasis, dry and sensitive skin).
2019
Personalized skincare
Listed as a pre-seed round with LEO Pharma as lead investor.
Listed as a seed round; lead investor and amount not specified in provided evidence.
12000000.00
Series A reported at $12M with participation from Inventure and existing investors.
“Series A led by Talis Capital with participation from Inventure and existing investors; earlier pre-seed support included LEO Pharma.”